Market closed · After hours · 5:42 PM ET
Last update: Aug 26, 2026, 5:08 PM ET
Madrigal Pharmaceuticals, Inc.
$538.88 5.22% today
After Hours

Why Madrigal Pharmaceuticals, Inc. (MDGL) stock moved

Updated Aug 26, 2026

Madrigal Pharmaceuticals, Inc. (MDGL) shares climbed 5.2% to $538.88 as of August 26, 2026, a significant gain from the prior close of $512.16. BestStocks flagged the session as a major change for MDGL. Below, we break down what changed for MDGL, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

MDGL climbed 5.2% to $538.88

Madrigal Pharmaceuticals rose 6.18% to $543.81 following major institutional investor disclosures in SEC 13F filings released August 26. Paulson & Co. disclosed a new position of over 1.34 million shares (~$719.5 million), making MDGL its largest portfolio holding, while Bank of New York Mellon Corp and J. Goldman & Co. also took fresh positions. Volume was below average at 0.59x expected for this time of session. Madrigal's earnings release scheduled for November 3, 2026 (consensus EPS estimate: −$0.91); also monitor for any follow-on institutional filings or analyst commentary responding to the 13F disclosures.

This summary describes the catalyst and move as first detected on Aug 26, 2026, 2:18 PM EDT; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
ValuationLow confidence
Rel. volume
1.0×
Normal
Vs peers
No comparable peers
Market cap
$12.5B
NASDAQ Global Select
Analyst target
$677
+25.6% vs price
Price chart
Jul 27 – Aug 26
VVVEFEEEFEEE$466$509$552Jul 27Aug 4Aug 11Aug 19Aug 26
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Madrigal Pharmaceuticals, Inc. investors

For Madrigal Pharmaceuticals, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Material positive event; Strong 5.2% price move. Weighing against that: Madrigal Pharmaceuticals filed an 8-K material event report today (SEC mdgl-20260730.htm) coinciding with an earnings report, triggering a 14.28% intraday decline to $468.76; Madrigal Pharmaceuticals, Inc. (MDGL) moved -3.21% from $553.48 to $535.69 on 2026-07-20. Wall Street's consensus price target sits at $677.00, implying +25.6% upside from $538.88. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality low (59/100). With earnings roughly 69 days out, the next report is the most likely near-term test of the move.

MDGL price reaction

MDGL last traded at $538.88, up $26.72 (+5.22%) from the previous close of $512.16. The session traded on 1.0× average volume (normal), so participation was unremarkable. Over the past month the stock has ranged between $467.32 and $551.25, and it currently sits about 85% of the way up that band.

Bullish and bearish analyst opinions on Madrigal Pharmaceuticals, Inc. (MDGL)

Latest catalyststrengthens the bull case
The latest catalyst — a materially positive development — it strengthens the bull case and confirms the prevailing bullish analyst lean.

The consensus analyst price target on Madrigal Pharmaceuticals, Inc. (MDGL) is $677.00, 25.6% above the recent $538.88. Over the past 90 days analysts logged 1 upgrade, 3 maintains, and 0 downgrades. Here is how the bullish and bearish cases on MDGL line up.

The bullish case

  • Wall Street's consensus price target of $677.00 implies +25.6% upside from $538.88.
  • The Street's most bullish target is $962.00 (+78.5%).
  • 1 analyst upgrade in the past 90 days, most recently Wolfe Research to Outperform (2026-08-04).
  • Material positive event.
  • Strong 5.2% price move.

The bearish case

  • Madrigal Pharmaceuticals filed an 8-K material event report today (SEC mdgl-20260730.htm) coinciding with an earnings report, triggering a 14.28% intraday decline to $468.76.
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Aug 26, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $677+25.6%
1 upgrades= 3 maintains
Wolfe Research upgraded to Outperform · 2026-08-04
SEC filings watch
8-K2026-08-12
Material event — review for impact
high
10-Q2026-07-30
Quarterly financial results
medium
8-K2026-07-30
Material event — review for impact
high
8-K2026-06-17
Material event — review for impact
high
Peer context
MDGL+5.2%

Previous notable changes for MDGL

Material / Earnings2026-08-20-3.9%
Madrigal Pharmaceuticals, Inc. (MDGL) moved −2.92% from $534.69 to $519.09 on 2026-08-20. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average, indicating routine trading.
Material / Earnings2026-08-17+3.4%
Madrigal Pharmaceuticals, Inc. (MDGL) moved +3.36% from $507.83 to $524.87 on 2026-08-17. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average.
Material / Earnings2026-08-13-5.4%
Madrigal Pharmaceuticals, Inc. (MDGL) moved -4.92% from $533.65 to $507.37 on 2026-08-13. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average, suggesting the move was not driven by unusual trading activity.
Filings2026-08-12+0.2%
Madrigal Pharmaceuticals, Inc. (MDGL) filed a new 8-K on August 12, 2026. The audit found no details on the form's specific disclosures.

In-depth MDGL event analyses

Permanent, dated analyses of MDGL's most significant sessions.
Upcoming catalysts & outlook
Next earnings
2026-11-03 (est.)
in 69 days
Earnings Release
2026-11-03
High impact
Thesis shift
Neutral / Mixed
bullish signal
Risk level
High
from change events

Frequently asked questions about MDGL

Why did Madrigal Pharmaceuticals, Inc. (MDGL) stock move?

MDGL climbed 5.2% to $538.88. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.

How much did MDGL stock rise?

MDGL gained 5.22% ($26.72) versus the prior close of $512.16, last trading at $538.88 on 1.0× average volume.

When is Madrigal Pharmaceuticals, Inc.'s next earnings date?

MDGL's next earnings report is estimated for 2026-11-03 — about 69 days away.

What is the analyst price target for MDGL?

The consensus analyst price target for MDGL is $677.00, about 25.6% above the current $538.88. Over the past 90 days, analysts recorded 1 upgrade, 3 maintains, and 0 downgrades.

How BestStocks tracks MDGL

This page is generated automatically by BestStocks' change-detection system after its price and volume cleared MDGL-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for MDGL, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of August 26, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataSEC EDGAR filingsFMP earnings & estimatesAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.